Monopar Therapeutics MNPR 深 沪
交易中 05-19 11:06:35 美东时间
56.60
+0.350
+0.62%
华盛通- 最 高58.49
- 今 开55.50
- 成交量 9.24万股
- 最 低 55.50
- 昨 收 56.25
- 总市值 3.79亿
- 52周最高 105.00
- 市盈率 静 --
- 换手率 1.38%
- 52周最低 29.18
- 委 比 -98.02%
- 总股本 669.91万
- 历史最高 240.00
- 量 比 1.67
- 振 幅 5.32%
- 历史最低 1.3695
- 每 手 1
- 风险率 18.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics announced its Q1 2026 financial results and business updates. The company remains on track to submit the NDA for ALXN1840 for Wilson Disease in mid-2026. Recent data from the FoCus trial showed greater neurologic benefits of ALXN1840 over standard of care. The company also presented results at major neurology and liver disease conferences. Cash and investments as of March 31, 2026, were $137.5 million, with net loss of $3.9 m...
05-14 18:00
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Therapeutics announced positive Phase 3 FoCus trial results for ALXN1840 in Wilson disease patients with neurologic symptoms, showing greater neurologic benefit vs standard of care. At Week 48, 25% of SoC patients vs 9% of ALXN1840-treated patients experienced neurologic worsening (p=0.038), while 45% of ALXN1840 patients vs 32% of SoC patients showed improvement. ALXN1840 also demonstrated durable neurologic benefit over 3 years and a fa...
04-19 23:00
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16
Monopar Therapeutics press release (MNPR): Q4 GAAP EPS of -$0.61 misses by $0.16. Cash, cash equivalents and short-term investments as of December 31, 2025, were $140.4 million. More on Monopar Therap...
03-28 04:47
Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 72.65 percent increase over losses of $(2.23) per share
03-28 01:06
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Therapeutics reported positive developments in 2025, including progress on ALXN1840 for Wilson disease, with plans to submit an NDA in mid-2026. The company strengthens leadership with Susan Rodriguez as Chief Commercial and Strategy Officer. 2025 financial results show a reduced net loss, with $140.4 million in cash reserves supporting operations through 2027. ALXN1840 demonstrated favorable safety and efficacy in multiple studies, and M...
03-27 17:00
Monopar Therapeutics Appoints Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics Appoints Susan Rodriguez as Chief Commercial and Strategy Officer Monopar Therapeutics Inc. appointed Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In the newly created role, Rodriguez will lead the company’s commercial strategy and build-out a
03-02 21:01
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics Inc. has appointed Susan Rodriguez as Chief Commercial and Strategy Officer. In this role, she will lead the company's commercial strategy and infrastructure development as it prepares to submit an NDA for ALXN1840, its investigational therapy for Wilson disease. With over 30 years of experience in biopharmaceutical leadership, Rodriguez brings a proven track record of successfully launching rare disease therapies and scaling...
03-02 13:00
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target
BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.
02-23 20:55
美股大行评级 | 英特尔、美光科技、SanDisk等获大行上调目标价；纽约梅隆银行获5家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Rezolve AI"买入"评级，目标价从10美元升至12美元；HC Wainwright & Co.：维持Largo"买入"评级，目标价从2.9美元升至3.1美元
01-15 16:10
